Structure-guided design of peptidic ligand for human prostate specific antigen

Journal of Peptide Science

Volumn 13, Issue 12, 2007, Pages 849-855

  Hassan, M D Imtaiyaz ^a   Kumar, Vijay ^a   Somvanshi, Rishi K ^a   Dey, Sharmistha ^a   Singh, Tej P ^a   Yadav, Savita ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Chymotiypsin; Kallikrein; Peptide inhibitor; Prostate carcinoma; Structure based drug design; Three dimensional structure; Tumor proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; SYNTHETIC PEPTIDE; TUMOR MARKER;

ANTIGEN BINDING; ANTIGEN PURIFICATION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVITY; FLUORESCENCE SPECTROSCOPY; HUMAN; HYDROPHOBICITY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; SEMINAL PLASMA;

BINDING SITES; HUMANS; HYDROPHOBICITY; LIGANDS; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; SPECTROMETRY, FLUORESCENCE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE; TIME FACTORS;

EID: 37349015525     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.911     Document Type: Article

References (45)

1. Watt KW, Lee Pd, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc. Natl. Acad. Sci. U.S.A. 1986; 83: 3166-3170.
2. Digby M, Zhang XY, Richards RI. Human prostate specific antigen (PSA) gene: structure and linkage to the kallikrein-like gene, hGK-1. Nucleic Acids. Res 1989; 17: 2137.
3. Lilja H, Abrahamsson PA, Lundwall A. Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J. Biol. Chem. 1989; 264: 1894-1900.
4. Satoh S, Ujiie T, Kubo T, Ohhori T, Iwasaki T, Satodate R, Numasato S. Prostatic epithelial polyp of the prostatic urethra. Eur. Urol. 1989; 16: 92-96.
5. Malatesta M, Mannello F, Sebastiani M, Bianchi G, Gazzanelli G. Prostate-specific antigen found in type I breast cyst fluids is a secretory product of the apocrine cells lining breast gross cysts. Breast Cancer Res. Treat. 1999; 57: 157-163.
6. Diamandis EP, Nadkarni S, Bhaumik B, et al. Immunofluorometric assay of pepsinogen C and preliminary clinical applications. Clin. Chem. 1997; 48: 1365-1371.
7. Maeda K, Sueishi K. A monoclonal antibody that defines basal cells of stratified epithelia in various human and rabbit tissues. Histochemistry 1989; 92: 319-324.
8. Shibata K, Kajihara J, Kato K, Hirano K. Purification and characterization of prostate specific antigen from human urine. Biochim. Biophys. Acta 1997; 1336: 425-433.
9. Zaviacic M, Ablin RJ. The female prostate and prostate-specific antigen. Immunohistochemical localization, implications of this prostate marker in women and reasons for using the term "prostate" in the human female. Histol. Histopathol. 2000; 15: 131-142.
10. Kato H, Kobayashi S, Islam AM, Nishizawa O. Female paraurethral adenocarcinoma: histological and immunohistochemical study, Int. J. Urol. 2005; 12: 117-119.
11. Bilhartz DL, Tindall DJ, Oesterling JE. Prostate-specific antigen and prostatic acid phosphatase: biomolecular and physiologic characteristics. Urology 1991; 38: 95-102.
12. Lilja H. Structure, function, and regulation of the enzyme activity of prostate-specific antigen. World J. Urol. 1993; 11: 188-191.
13. Pijoan JM. Diagnostic methodology for the biochemical recurrence of prostate cancer after radiotherapy. Arch Esp. Urol. 2006; 59: 1053-1062.
14. Grossklaus DJ, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. Urol. Oncol. 2002; 7: 195-198.
15. Babaian Rd, Fritsche HA, Evans RB. Prostate-specific antigen and prostate gland volume: correlation and clinical application. J. Clin. Lab. Anal. 1990; 4: 135-137.
16. Steuber T, Vickers A, Haese A, et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int. d. Cancer 2007; 120: 1499-1504.
17. McCabe NP, Angwafo FF III, Zaher A, Selman SH, Kouinche A, Jankun J. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol. Rep. 2000; 7: 879-882.
18. Cohen P, Peehl DM, Graves HC, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease, J. Endocrinol. 1994; 142: 407-415.
19. Yoshida E, Ohmura S, Sugiki M. Maruyama M, Mihara H. Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. Int. J. Cancer 1995; 63: 863-865.
20. Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 1991; 37: 1618-1625.
21. Lilja H, Cockett AT, Abrahamsson PA. Prostate specific antigen predominantly forms a complex with alpha 1-antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum. Cancer 1992; 70: 230-234.
22. Zhang WM, Finne P, Leinonen J, Stenman UH. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases. Scand. J. Clin. Lab. Invest. Suppl. 2000; 233: 51-58.
23. Espana F, Navarro S, Medina P, Zorio E, Estelles A. The role of protein C inhibitor in human reproduction. Semin. Thromb. Hemost. 2007; 33: 41-45.
24. Otto A, Bar J, Birkenmeier G. Prostate-specific antigen forms complexes with human alpha 2-macroglobulin and binds to the alpha 2-macroglobulin receptor/LDL receptor-related protein. J. Urol. 1998; 159: 297-303.
25. Finne P, Zhang WM, Auvinen A, et al. Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer. J. Urol. 2000; 164: 1956-1960.
26. Qian Y, Sensibar JA, Zelner DJ, et al. Two-dimensional gel electrophoresis detects prostate-specific antigen-alpha1-antichymotrypsin complex in serum but not in prostatic fluid. Clin. Chem. 1997; 43: 352-359.
27. Malm J, Hellman J, Hogg P, Lilja H. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate 2000; 45: 132-139.
28. Bhuiyan MM, Li Y, Banerjee S, et al. Down-regulation of androgen receptor by 3,3′-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res. 2006; 66: 10064-10072.
29. Agoulnik IU, Vaid A, Nakka M, et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006; 66: 10594-10602.
30. de Lamirande E. Semenogelin, the main protein of the human semen coagulum, regulates sperm function. Semin. Thromb. Hemost. 2007; 88: 60-68.
31. Dehm SM, Tindall DJ. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J. Biol. Chem. 2006; 281: 27882-27893.
32. Quayle SN, Mawji NR, Wang J, Sadar MD. Androgen receptor decoy molecules block the growth of prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 1331-1336.
33. Tahmatzopoulos A, Gudegast C, Stockle M, et al. Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer. Aktuelle Urol. 2004; 35: 491-496.
34. Leinonen J, Wu P, Koivunen E, Narvanen A, Stenman UH. Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen. Scand. J. Clin. Lab. Invest. Suppl. 2000; 233: 59-64.
35. Szabo A, Stolz L, Granzow R. Surface plasmon resonance and its use in biomolecular interaction analysis (BIA). Curr. Opin. Struct. Biol. 1995; 5: 699-705.
36. Acevedo B, Perera Y, Torres E, Penton D, Ayala M, Gavilondo J. Fast and novel purification method to obtain the prostate specific antigen (PSA) from human seminal plasma. Prostate 2006; 66: 1029-1036.
37. Bindukumar B, Kawinski E, Cherrin C, et al. Two step procedure for purification of enzymatically active prostate-specific antigen from seminal plasma. J. Chromatogr. B, Analyt. Technol. Biomed. Life Sci. 2004; 813: 113-120.
38. Hassan MI, Kumar V, Singh TP, Yadav S. Structural model of human PSA: A target for prostate cancer therapy. Chem Biol Drug Des. 2007; 70(3): 261-267.
39. Villoutreix BO, Getzoff ED, Griffin JH. A structural model for the prostate disease marker, human prostate-specific antigen. Protein Sci. 1994; 3: 2033-2044.
40. Wolfe C, Cladera J, O'Shea P. Amino acid sequences which promote and prevent the binding and membrane insertion of surface-active peptides: comparison of melittin and promelittin. Mol. Membr. Biol. 1998; 15: 221-227.
41. Golding C, Senior S, O'Shea P. Interaction of a signal peptide with phospholipid vesicles: the kinetics of binding, insertion and structural changes. Biochem. Soc. Trans. 1995; 23: 554S.
42. Nieba L, Krebber A, Pluckthun A. Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics. Anal. Biochem. 1996; 284: 155-165.
43. Chen Z, Bode W. Refined 2.5 A X-ray crystal structure of the complex formed by porcine kallikrein A and the bovine pancreatic trypsin inhibitor. Crystallization, Patterson search, structure determination, refinement, structure and comparison with its components and with the bovine trypsin-pancreatic trypsin inhibitor complex. J. Mol. Biol. 1983; 164:283-311.
44. Bode W, Chen Z. The X-ray structures of porcine pancreatic kallikrein and of its complex with bovine pancreatic trypsin inhibitor. Adv. Exp. Med. Biol. 1983; 156: 289-308.
45. Del Nery E, Chagas JR, Juliano MA, Juliano L, Prado ES. Comparison of human and porcine tissue kallikrein substrate specificities. Immunopharmacology 1999; 45: 151-157.